By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Protalix Biotherapeutics, Inc. 

2 Snunit St.
Science Park
Carmiel      Israel
Phone: 972-4-9028100 Fax: 972-4-988-9489


SEARCH JOBS


Industry
Biotechnology

Segment
Biotechnology





Company News
Protalix Biotherapeutics, Inc. (PLX) Announces Positive Results From Phase II Clinical Trial Of Alidornase Alfa (AIR Dnase) For The Treatment Of Cystic Fibrosis 4/12/2017 10:22:33 AM
Protalix Biotherapeutics, Inc. (PLX) Announces Additional Positive Data From Its Phase I/II Clinical Trial For PRX-102 For The Treatment Of Fabry Disease 8/10/2016 7:55:34 AM
Protalix Biotherapeutics, Inc. (PLX) Reports Fiscal Year 2015 Financial Results And Provides Corporate Update 3/8/2016 8:21:30 AM
Protalix Biotherapeutics, Inc. (PLX) Presents Positive Six And Twelve Month Interim Clinical Data On PRX-102 For The Treatment Of Fabry Disease At The 12th Annual Worldsymposium 2016 3/3/2016 7:43:05 AM
Protalix Biotherapeutics, Inc. (PLX) To Participate In The Suntrust Robinson Humphrey Orphan Drug Day And The 12th Annual Worldsymposium 2016 2/22/2016 11:56:03 AM
Protalix Biotherapeutics, Inc. (PLX) To Conduct Phase III Clinical Trial For PRX-102 For The Treatment Of Fabry Disease Following A Successful End-Of-Phase II Meeting With FDA 11/16/2015 7:42:07 AM
Protalix Biotherapeutics, Inc. (PLX) Reports Third Quarter 2015 Financial Results 11/10/2015 8:02:38 AM
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Long Term Data On PRX-102 For Fabry Disease 10/19/2015 7:28:44 AM
Protalix Biotherapeutics, Inc. (PLX) To Present At The Rodman & Renshaw 16th Annual Global Investment Conference 9/4/2014 10:10:13 AM
Pfizer Inc. (PFE) And FDA Announce Protalix Biotherapeutics, Inc. (PLX) Approval Of Pediatric Indication For ELELYSO™ (taliglucerase alfa) For Injection, For Intravenous Use For The Treatment Of Type 1 Gaucher Disease 8/29/2014 11:00:08 AM
123
//-->